As a reversible inhibitor that targets both CPT1A and CPT1B, perhexiline maintains anti-cancer efficacy while demonstrating reduced cardiotoxicity in preclinical chronic lymphocytic leukemia (CLL) and hepatocellular carcinoma (HCC) [105,106]. The gene discussed is CPT1A; the disease is B-cell chronic lymphocytic leukemia.